Lifecore Signs Sixth Ophthalmic Manufacturing Deal for Pre-Filled Syringe Reformulation
LFCR•Lifecore Biomedical signed a manufacturing services agreement with an ophthalmic customer to perform process development and technical transfer for a next-generation injectable reformulation from vials to pre-filled syringes. This sixth late-stage pipeline addition in seven months highlights Lifecore’s injectable CDMO strength and readies it for commercial manufacturing upon regulatory approval.
1. Manufacturing Agreement Details
Lifecore entered into a manufacturing services agreement with an ophthalmic customer, under which it will execute process development and technical transfer to enable a next-generation injectable product’s shift from vials to pre-filled syringe format. This work prepares the program for anticipated commercial-scale production once regulatory clearance is achieved.
2. Pipeline Expansion
This marks Lifecore’s sixth late-stage program addition within seven months, reinforcing its growth in ophthalmic injectables. The expanding portfolio reflects strong demand for specialized CDMO capabilities and supports Lifecore’s broader strategy of sustainable long-term growth.
3. Strategic Outlook
By enhancing its syringe-based manufacturing offerings, Lifecore strengthens its position in the fast-growing injectable ophthalmic market. Successful execution of this technical transfer could drive future revenue streams and showcase Lifecore’s ability to support reformulation programs for global biopharma clients.
